Key result
Patients receiving drug-eluting stents remain at a 1% to 2% risk of stent thrombosis, necessitating a minimum of 12 months of uninterrupted dual-antiplatelet therapy.
Emphasizes the critical need for at least 12 months of dual-antiplatelet therapy following drug-eluting stent implantation to mitigate the risk of stent thrombosis.
D rug-eluting stents (DES) have revolutionized the ap- proach to percutaneous coronary interventions and have substantially reduced restenosis compared with bare metal stents. Despite their advantages, DES are not without disadvantages. In particular, patients who receive DES remain at risk of a 1% to 2% incidence of stent thrombosis, which is often fatal. Dual-antiplatelet therapy (DAT) in the form of a thienopyridine and aspirin improves outcomes in patients who receive DES, Consequently, recommendations for the sirolimus-eluting stent and the paclitaxeleluting stent include a minimum of 12 months of uninterrupted thienopyridine therapy, while maintaining long-term aspirin therapy for the patients' underlying coronary disease. s such, early discontinuation of a thienopyridine should only be considered if bleeding risk substantially outweighs thrombotic risk or considered temporarily if a major invasive procedure is necessary.
No takes yet. Share an insight, caveat, or question.
Jarvie et al. (2010) conducted an editorial in Coronary disease requiring drug-eluting stents. Dual-antiplatelet therapy (thienopyridine and aspirin) was evaluated. Patients receiving drug-eluting stents remain at a 1% to 2% risk of stent thrombosis, necessitating a minimum of 12 months of uninterrupted dual-antiplatelet therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: